Boston Scientific (BSX) Stock Sinks As Q3 Results Reset Growth Expectations

Boston Scientific stock dropped 5.8% to close at US$42.43 after its Q3 2026 report, as traders focused on a softer quarter and guidance reset. The headline was clear. Organic revenue growth of 1.5% and adjusted earnings per share below the company’s own target range landed with a thud in a market used to cleaner execution.

Step back from the one day selloff and a different picture starts to form. Trailing 12 month net income of US$3.5b and a P/E of 17.6x against higher industry multiples point to a business that is still generating substantial cash and earnings power, even as it works through a cyber hit and pressure in key cardiac franchises.

If you appreciate the earnings engine behind Boston Scientific but are uneasy about a soft quarter and the risk of a guidance reset, consider reviewing our curated list of resilient balance sheet ideas in the list of solid balance sheet and fundamentals stocks (24 results)

Q3 2026 Earnings Summary

• Total Revenue (Q3 2026 vs Q3 2025): US$5,138m vs. US$5,065m (up 1.4%)
• Net Income, Excluding Extra Items (Q3 2026 vs Q3 2025): US$582m vs. US$755m (down 22.9%)
• Basic EPS (Q3 2026 vs Q3 2025): US$0.40 vs. US$0.51 (down 21.2%)
• Adjusted Operating Margin (Q3 2026 vs Q3 2025): 26.5% vs. approximately 28.0% (down about 150 basis points)

Management just labeled 2027 Boston Scientific’s trough year on the call. Ask Charlie what makes Boston Scientific call 2027 the trough.

Evaluating Boston Scientific’s Bullish Growth Engines Against Q3

The bullish story centers on high impact procedure platforms scaling into stronger earnings power for Boston Scientific.

"Broad-based adoption of pulsed field ablation for atrial fibrillation, with Boston Scientific indicating high PFA usage in the U.S. and expanding access in Europe, Japan and China, supports procedure volumes and is set up to influence revenue and operating leverage as the EP franchise scales further."

Q3 puts that ambition under pressure. Electrophysiology revenue declined 5% with U.S. EP down 8%, and management flagged continued share erosion and tougher PFA competition into 2027. Operating margin compressed by about 150 basis points, so the expected operating leverage from EP scale has not appeared in the current numbers.

Not everyone reads the same price the same way. → See the higher figure this Narrative lands on, and how it gets there.

Boston Scientific Bear Case Hits Early Milestones

The cautious view on Boston Scientific argues that electrophysiology and WATCHMAN could struggle to convert large patient pools into profitable, sustained growth.

"Reimbursement and hospital capacity constraints, especially for stand alone WATCHMAN procedures and sacral neuromodulation, may limit how much of that demand translates into higher net margins."

Q3 results line up with that concern. WATCHMAN revenue declined 6%, with U.S. stand alone procedures falling in the high teens even as concomitant cases climbed 35%. EP sales slipped 5% and U.S. EP dropped 8%. Adjusted gross and operating margins both compressed, so the margin drag highlighted in the bearish narrative is already visible in reported numbers.

Hunt For Mispriced Earnings Power

Boston Scientific highlights how guidance changes can unsettle expectations even in widely followed names. The real opportunity is in studying businesses that might be mispriced before consensus revises its view.

• Company 1 - 38% below our estimate - uses subsidy-linked trade-in programs and refurbishing technology to convert discarded devices into recurring recommerce activity.
• Company 2 - 40% below our estimate - builds tracker and control systems that solar developers secure early so future storage and inverter upgrades remain with one supplier.
• Company 3 - 23% below our estimate - installs robotic surgery platforms that hospitals adopt for higher acuity joint procedures after early users demonstrate workable throughput and staffing.

That is three of the list. See every one of the 29 undervalued companies on it →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com